jwci.org

GENERAL
META
HTML
LINK ANALYSIS
SERVER
IP

Jwci.org recives any estimated n/a unique visitors and n/a unique page views per day. Revenue gained from these much visits may be n/a per day from various advertising sources. The estimated worth of site is n/a.

Website Age n/a
Alexa Rank no-data
Country United States
IP Address 104.197.14.93

META INFORMATION

Title

Advanced Cancer Research and Treatment | John Wayne Cancer Inst**ute

Description

John Wayne Cancer Inst**ute translates advanced cancer research into personalized treatment. Learn about our treatment options and dedication to cure cancer

Keywords

Content Type

utf-8

No	Meta Name	Value
1	designer	www.emagine.com
2	viewport	width=device-width, initial-scale=1
3	robots	index, follow

GENERAL HTML INFORMATION

Type	Status
HTML 5
Responsive Website

HTML SIZE INFORMATION

Text / Code Ratio 5.10 %

jwci.org has a website text/code ratio of 5.10 %. Search engine crawlers tend to not pick up pages with inadequate content.

IMPORTANT HTML TAGS AND COUNTS

Titles

H11
H210
H316
H44
H50
H60

No	Text
1	Translating advanced cancer research into personalized, pa***ionate treatment.

No	Text
1	Steven o’day, md, executive director of the john wayne cancer ınst**ute & director of providence los angeles regional research
2	Cancer ınnovation newsletter
3	Clinical trials
4	Attracting patients from around the world
5	Fellows***p opportunities
6	Latest news & events
7	Latest news from our blog
8	ı want to:
9	Connect with us:
10	About john wayne cancer ınst**ute

No	Text
1	Urology and urologic oncology
2	Melanoma, skin and soft tissue tumors
3	Endocrine tumors and disorders
4	Breast surgery and oncology
5	Minimally ınvasive chest surgery and thoracic surgical oncology
6	Gastrointestinal and hepatobiliary tumors
7	Gynecologic oncology
8	Translational research departments
9	Brain tumors & neuroscience
10	Complex surgical oncology fellows***p
11	Urologic oncology fellows***p
12	Neurosurgical fellows***p
13	Postdoctoral lab-based translational molecular medicine fellows***p
14	Olaparib for metastatic castration-resistant prostate cancer
15	Physiological and pathological roles of cdk5: potential directions for therapeutic targeting in neurodegenerative disease
16	Ang1005, a brain penetrating peptide-drug conjugate, shows activity in patients with breast cancer with leptomeningeal carcinomatosis and recurrent brain metastases

No	Text
1	Lung cancer awareness
2	Parathyroid awareness month
3	Sunscreen benefits and safety
4	Genomic sequencing center

Text Styling

STRONG1
B0
EM1
I0
U0
CITE0

STRONG

No	Text
1	Cancer Innovation

No	Text
1	Cancer Innovation

LINK ANALYSIS

Total Link Count: 108

Internal Link Count : 95

No	Text	Type
1	About JWCI	text
2	About Us	text
3	Research Administration	text
4	Our Hospital	text
5	Giving	text
6	Technologies Available	text
7	Cancer Innovation Newsletter	text
8	News	text
9	Events	text
10	Blog	text
11	Video Library	text
12	JWCI Directory & Phone Number	text
13	Centers of Excellence	text
14	Urology and Urologic Oncology	text
15	Melanoma, Skin and Soft Tissue Tumors	text
16	Endocrine Tumors and Disorders	text
17	Minimally Invasive Chest Surgery and Thoracic Surgical Oncology	text
18	Gastrointestinal and Hepatobiliary Tumors	text
19	Breast Surgery and Oncology	text
20	Gynecologic Oncology	text
21	Brain Tumors & Neuroscience	text
22	Translational Research Departments	text
23	Fellows***p Programs	text
24	Fellows***p Overview	text
25	Surgical Oncology Fellows***p	text
26	Urology Fellows***p	text
27	Neurosurgery Fellows***p	text
28	Translational Molecular Medicine Fellows***p	text
29	Philanthropy Sponsored Programs	text
30	Clinical Trials	text
31	Find A Clinical Trial	text
32	Clinical Trials FAQs	text
33	Partic****te In A Clinical Trial	text
34	COVID-19 Clinical Trials	text
35	Cancer Support Services	text
36	Meet our Team	text
37	Psychiatry	text
38	Social Work	text
39	Nutrition	text
40	Survivors***p	text
41	Palliative Care	text
42	Rehabilitation	text
43	Genetics	text
44	Bone Health	text
45	Spiritual Care	text
46	Ongoing Providence Saint John’s Cla***es and Groups	text
47	Inspiring Stories	text
48	Supportive Care Research	text
49	Patient and Caregiver Resources	text
50	Contact Us	text

External Link Count : 13

No	Text	Type
1	My Chart	text
2	Publication Olaparib for Metastatic Castration-Resistant Prostate Cancer Przemyslaw W. Twardowski, M.D., and his colleagues, have published a new study in the New England Journal of Medicine, which demonstrates significant benefit of therapy with olaparib (PARP inhibitor) in patients with advanced prostate cancer who harbor certain mutations of DNA repair system and who failed standard treatments. Based on the results of that study on 5/19/2020 Food and Drug Administration (FDA) granted approval of olaparib, providing a valuable treatment option for about 25% of patients with advanced prostate cancer with certain mutations of DNA repair. These mutations can be detected by performing an analysis of a patient’s cancer specimen and sometimes also on a specialized blood test. Learn More	text
3	Publication Physiological and Pathological Roles of Cdk5: Potential Directions for Therapeutic Targeting in Neurodegenerative Disease The Drug Discovery and Nanomedicine Laboratory (Yenugonda V and Waters A), along with Kesari S, and Allnutt AB, presents a review article in ACS Chemical Neuroscience highlighting the importance of Cdk5 activity and function in the brain and demonstrates how deregulation of Cdk5 can contribute to the development of neurodegenerative conditions such as Alzheimer’s and Parkinson’s disease. Learn More	text
4	Publication ANG1005, a Brain Penetrating Peptide-Drug Conjugate, Shows Activity in Patients With Breast Cancer With Leptomeningeal Carcinomatosis and Recurrent Brain Metastases The department of Translational Neurosciences & Neurotherapeutics studied ANG1005, a novel taxane derivative, which consists of 3 paC****axel molecules covalently linked to Angiopep-2, designed to cross the blood-brain and blood-cerebrospinal barriers and to penetrate malignant cells via LRP1 transport system. Read the publication to learn the results. Learn More	text
5	-	image
6	-	image
7	-	image
8	-	image
9	Careers	text
10	Facebook	text
11	LinkedIn	text
12	Twitter	text
13	Instagram	text